Système d'expression: Plateformes d'expression mammifères et microbiennes
Pays d'origine: la Suisse ; les États-Unis
Application: Développement de lignées cellulaires de bout en bout couvrant les plateformes d'expression mammifères et microbiennes, permettant une production à haut rendement de produits biologiques complexes et de biosimilaires

Autres informations

Description supplémentaire:

KBI Biopharma provides cell line development spanning mammalian and microbial expression platforms to speed biotherapeutic development from gene to GMP. Its mammalian offering includes CHO-M Selexis SUREtechnology, CHO-ZN, CHO-DG44, CHO-S, and CHO-K1 GS platforms for robust, scalable, high-titer lines suited to complex molecules like mAbs, Fc-fusion proteins, and ADCs, while its microbial offering uses E. coli-based platforms, including off-the-shelf and engineered strains, for early-stage material or scalable production of peptides, enzymes, and other recombinant proteins, letting clients pick the expression system that best fits their molecule's complexity and clinical timeline.